Patents by Inventor Kirill Lyapichev

Kirill Lyapichev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PERFORIN 2 DEFENSE AGAINST INVASIVE AND MULTIDRUG RESISTANT PATHOGENS
    Publication number: 20170191058
    Abstract: Perforin-2 (P2) is expressed by fibroblasts, microglia and macrophages and was found to be responsible for killing bacteria, for example, Mycobacteria smegmatis, M. avium, Salmonellae, MRSA (drug resistant Stapholococci), E. coli. Compounds identified by screening assays are selected based on the effects of these compounds on P2. Use of these compounds in the treatment of infectious diseases, in particular, bacteria and antibiotic-resistant bacteria is also provided.
    Type: Application
    Filed: September 1, 2016
    Publication date: July 6, 2017
    Inventors: Lesley De Armas, Kirill Lyapichev, Ryan McCormack, Eckhard Podack
  • PERFORIN 2 DEFENSE AGAINST INVASIVE AND MULTIDRUG RESISTANT PATHOGENS
    Publication number: 20160054299
    Abstract: Perforin-2 (P2) is expressed by fibroblasts, microglia and macrophages and was found to be responsible for killing bacteria, for example, Mycobacteria smegmatis, M. avium, Salmonellae, MRSA (drug resistant Stapholococci), E coli. Compounds identified by screening assays are selected based on the effects of these compounds on P2. Use of these compounds in the treatment of infectious diseases, in particular, bacteria and antibiotic-resistant bacteria is also provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 25, 2016
    Inventors: Lesley De Armas, Kirill Lyapichev, Ryan McCormack, Eckhard Podack
  • PERFORIN 2 DEFENSE AGAINST INVASIVE AND MULTIDRUG RESISTANT PATHOGENS
    Publication number: 20150204845
    Abstract: Perforin-2 (P2) is expressed by fibroblasts, microglia and macrophages and was found to be responsible for killing bacteria, for example, Mycobacteria smegmatis, M. avium, Salmonellae, MRSA (drug resistant Stapholococci), E coli. Compounds identified by screening assays are selected based on the effects of these compounds on P2. Use of these compounds in the treatment of infectious diseases, in particular, bacteria and antibiotic-resistant bacteria is also provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 23, 2015
    Inventors: Lesley De Armas, Kirill Lyapichev, Ryan McCormack, Eckhard Podack